文献速递心律失常

数据驱动的循环血液生物标志物与房颤相关的发现与验证

Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.
PubMed 文献 · Eur Heart J · 2019-01-01

结果显示年龄、男性、BMI、BNP升高和FGF-23升高与房颤独立相关,TRAIL-R2降低亦相关,生物标志物可改善房颤预测。

要点

  • 年龄、性别、BMI联合BNP和FGF-23可识别房颤患者。
  • 生物标志物较单纯临床危险因素改善房颤预测(NRI=0.178)。
  • 逻辑回归与机器学习验证AUC分别为0.684和0.697。

核心结论

  • 三个简单临床危险因素(年龄、性别、BMI)和两个生物标志物(BNP升高和FGF-23升高)可识别房颤患者。

研究设计与样本

  • 连续纳入638例已知房颤或≥2个CHA2DS2-VASc危险因素的患者,平均年龄70±12岁,男性398例(62%),房颤294例(46%)。
  • 采用前向选择逻辑回归和机器学习算法确定与房颤相关的临床危险因素、影像参数和生物标志物。

主要发现

  • 房颤与年龄显著相关(bootstrapped OR每岁=1.060,95%CI 1.04-1.10;P=0.001)。
  • 房颤与男性显著相关(OR=2.022,95%CI 1.28-3.56;P=0.008)。
  • 房颤与BMI显著相关(OR每单位=1.060,95%CI 1.02-1.12;P=0.003)。
  • 房颤与BNP升高显著相关(OR每倍变化=1.293,95%CI 1.11-1.63;P=0.002)。
  • 房颤与FGF-23升高显著相关(OR=1.667,95%CI 1.36-2.34;P=0.001),与TRAIL-R2降低显著相关(OR=0.242,95%CI 0.14-0.32;P=0.001)。

关键数值与推荐

  • 生物标志物较单纯临床危险因素改善房颤预测(净重分类改善=0.178;P<0.001)。
  • 逻辑回归和机器学习验证中预测房颤的AUC分别为0.684(95%CI 0.62-0.75)和0.697(95%CI 0.63-0.76)。

临床怎么用

  • 可考虑联合年龄、性别、BMI及BNP、FGF-23水平辅助识别房颤高风险患者。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Undetected atrial fibrillation (AF) is a major health concern. Blood biomarkers associated with AF could simplify patient selection for screening and further inform ongoing research towards stratified prevention and treatment of AF. METHODS AND RESULTS: Forty common cardiovascular biomarkers were quantified in 638 consecutive patients referred to hospital [mean ± standard deviation age 70 ± 12 years, 398 (62%) male, 294 (46%) with AF] with known AF or ≥2 CHA2DS2-VASc risk factors. Paroxysmal or silent AF was ruled out by 7-day ECG monitoring. Logistic regression with forward selection and machine learning algorithms were used to determine clinical risk factors, imaging parameters, and biomarkers associated with AF. Atrial fibrillation was significantly associated with age [bootstrapped odds ratio (OR) per year = 1.060, 95% confidence interval (1.04-1.10); P = 0.001], male sex [OR = 2.022 (1.28-3.56); P = 0.008], body mass index [BMI, OR per unit = 1.060 (1.02-1.12); P = 0.003], elevated brain natriuretic peptide [BNP, OR per fold change = 1.293 (1.11-1.63); P = 0.002], elevated fibroblast growth factor-23 [FGF-23, OR = 1.667 (1.36-2.34); P = 0.001], and reduced TNF-related apoptosis-induced ligand-receptor 2 [TRAIL-R2, OR = 0.242 (0.14-0.32); P = 0.001], but not other biomarkers. Biomarkers improved the prediction of AF compared with clinical risk factors alone (net reclassification improvement = 0.178; P < 0.001). Both logistic regression and machine learning predicted AF well during validation [area under the receiver-operator curve = 0.684 (0.62-0.75) and 0.697 (0.63-0.76), respectively]. CONCLUSION: Three simple clinical risk factors (age, sex, and BMI) and two biomarkers (elevated BNP and elevated FGF-23) identify patients with AF. Further research is warranted to elucidate FGF-23 dependent mechanisms of AF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chua W, Purmah Y, Cardoso VR, et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur Heart J. 2019. PMID: 30615112. doi:10.1093/eurheartj/ehy815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。